A randomized phase II study (B2151005) of the intravenous phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS metastatic colorectal cancer (mCRC).
TPS3649 Background: The combination of cetuximab plus irinotecan is considered a standard of care regimen for third-line treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC). However, the combination of cetuximab plus irinotecan provides limited tumor control and is associated with skin rash, diarrhea, and neutropenia. Thus, the need for more efficacious and better tolerated regimens remains high. Signaling through the phosphatidylinositol 3-kinase (PI3K) pathway is associated with resistance to a variety of antitumor agents. This association has been described in pre-clinical studies for cytotoxic chemotherapeutic agents with different mechanisms of action, including taxanes and DNA-damaging agents. In the clinic, activation of the PI3K pathway in tumors has been correlated with decreased response to therapy and worse clinical outcomes. Preliminary data from the phase I study B1271002 indicate that the combination of the intravenous PI3K/mammalian target of rapamycin (mTOR) inhib...